Ghent University Academic Bibliography

Show Sort by

Your filters: cql: keyword exact "therapy" cql: author exact 001960501655 or (type exact bookEditor and editor exact 001960501655)

Add to list
- Journal Article
- A1
- open access
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study

Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, et al.

(2023) ECLINICALMEDICINE. 56.
Add to list
Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?

Christian Brieghel, Veerle Galle (UGent) , Rudi Agius, Caspar Da Cunha-Bang, Michael A. Andersen, Philip Vlummens (UGent) , Mattias Mattsson, Richard Rosenquist, Karin E. Smedby, Carmen D. Herling, et al.

(2022) EUROPEAN JOURNAL OF HAEMATOLOGY. 108(5). p.369-378
Add to list
Isolated amyloidosis of the gastro-intestinal tract

Sander Smeets (UGent) , F. Dedeurwaerdere, E. Thomaere, B. Houthoofd, L. D'Hulst, P. Wilmes, Fritz Offner (UGent) and S. De Coninck

(2022) ACTA GASTRO-ENTEROLOGICA BELGICA. 85(1). p.80-84
Add to list
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Bene, Sonja Zweegman, Helene Caillon, Denis Caillot, et al.

(2021) LANCET ONCOLOGY. 22(10). p.1378-1390
Add to list
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S. P. Vermaat, Olivier Casasnovas, Nada Hamad, Josee M. Zijlstra, Sameer Bakhshi, et al.

(2020) LANCET HAEMATOLOGY. 7(7). p.E509-E522
Add to list
- Journal Article
- A1
- open access
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study

Marinus van Oers, Lukas Smolej, Mario Petrini, Fritz Offner (UGent) , Sebastian Grosicki, Mark-David Levin, Jaclyn Davis, Hiya Banerjee, Tommaso Stefanelli, Petra Hoever, et al.

(2019) BLOOD CANCER JOURNAL. 9.
Add to list
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study

Emmanuel Bachy, John F. Seymour, Pierre Feugier, Fritz Offner (UGent) , Armando Lopez-Guillermo, David Belada, Luc Xerri, John V. Catalano, Pauline Brice, Francois Lemonnier, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(31). p.2815-2824
Add to list
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

Xavier Leleu, Guillemette Fouquet, Valentine Richez, Stephanie Guidez, Alain Duhamel, Francois Machuron, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, et al.

(2019) CLINICAL CANCER RESEARCH. 25(14). p.4224-4230
Add to list
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2018) BLOOD. 132(23). p.2446-2455
Add to list
- Journal Article
- A1
- open access
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trneny, Fritz Offner (UGent) , Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, et al.

(2016) LANCET. 387(10020). p.770-778

Academic Bibliography

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study

Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?

Isolated amyloidosis of the gastro-intestinal tract

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study

Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study

Contents

Support

Contact